AGVC
Cross-Border Venture Accelerator 跨境创投加速平台

We Land the Science
That Improves Life.

专注投研全球长寿产业。
立足中国,放眼世界。

AGVC is the operating partner for deep-tech founders in aging, AI healthcare, and biotech — building the commercial, regulatory, and manufacturing foundation to land and scale across APAC.

AGVC 是深度科技创始人在亚太地区落地、扩张的核心运营伙伴,专注于抗衰老、AI 医疗健康及生物科技领域——为企业构建完善的商业化、合规及制造基础设施。

500+
Pipeline Companies
项目储备
3+
Service Paths
服务路径
Asia
Cross-Border
跨境布局
$4.2T
Silver Economy by 2035
2035年银发经济规模

Who We Serve

服务对象

Built for founders and partners who are ready to move.

专为准备好行动的创始人与合作伙伴而生。

🔬
Deep-Tech Startups
深度科技初创企业
You have validated science in longevity therapeutics, AI diagnostics, or biotech — and need an experienced operator to land it in Asia. We handle entity setup, grants, partnerships, and commercial introductions.
您拥有经过验证的长寿疗法、AI 诊断或生物科技成果,需要有经验的运营伙伴协助在亚洲落地。我们负责实体设立、政府资助、合作对接及商业化引荐。
Submit your company提交企业资料
🏭
CDMO & Manufacturing Partners
合同研发生产机构(CDMO)及制造商
You are a CDMO or life science supplier in the GBA or ASEAN looking to connect with global biotech and pharma companies seeking Asian production capacity. We broker the introduction and structure the deal.
您是大湾区或东盟的合同研发生产机构或生命科学供应商,希望与寻求亚洲产能的全球生物科技及制药企业建立联系。我们负责牵线搭桥并推进交易落地。
Explore partnership探索合作
🌐
Researchers & Tech Transfer Offices
科研机构及技术转让办公室
You are a scientist or TTO with IP that deserves a commercial life in Asia. We help you structure, protect, and license your assets to the right regional partners — without giving up control of your science.
您是拥有值得在亚洲商业化知识产权的科学家或技术转让办公室。我们帮助您架构、保护并授权资产给合适的区域合作伙伴——同时确保您对科研成果的掌控权。
Get in touch立即联系

The Opportunity

市场机遇

The numbers behind why this matters.

数据揭示为何此刻至关重要。

310M+
Chinese citizens aged 60+ — world's largest aging population
中国60岁以上人口——全球规模最大的老龄群体
Source: China National Bureau of Statistics, 2025
来源:中国国家统计局,2025年
$4.2T
Projected silver economy by 2035 — ~10% of China's GDP
预计2035年银发经济规模——约占中国GDP的10%
Source: CKGSB / World Bank, 2025
来源:长江商学院 / 世界银行,2025年
600K
Elderly-related enterprises in China by mid-2025
2025年中期中国涉老企业数量
Source: China Briefing / MOFCOM, 2025
来源:China Briefing / 中国商务部,2025年
$30B
Digital health market in China by 2025
中国数字健康市场规模(2025年)
Source: Statista Digital Health Report, 2025
来源:Statista数字健康报告,2025年

Our Thesis

我们的投资理念

Three forces converging — right now.

三股力量,正在此刻汇聚。

The world's first AI-driven venture catalyst dedicated to the longevity economy. Based in Hong Kong and New York, AGVC backs deep-tech founders at the frontier of healthcare, biotechnology, pharmaceutical innovation, and aging science — building the infrastructure to add 20+ healthy years to the human lifespan.

全球首家专注于长寿经济的AI驱动型创投催化剂。AGVC总部设于香港与纽约,支持医疗健康、生物技术、制药创新及抗衰老科学前沿的深度科技创始人——致力于为人类延长20年以上的健康寿命。

We are a hands-on cross-border accelerator that provides the commercial scaffolding, regulatory navigation, manufacturing access, and strategic partnerships that allow breakthrough science to land in and scale out of APAC. We operate a proprietary pipeline of 500+ global startups, with a team fluent across the boardroom, the clinic, and the cap table — scientists, physicians, capital markets veterans, and technology operators — united by a single thesis: that aging is the defining challenge, and opportunity, of our time.

我们是一家深度参与的跨境加速器,提供商业基础架构、监管路径规划、制造资源对接及战略合作伙伴关系,让突破性科研成果在亚太地区落地并规模化拓展。我们运营着一个拥有超过500家全球初创企业的专有项目管道,团队横跨商界、医疗与资本市场——科学家、医生、资本市场资深人士与科技运营者——凝聚于同一信念:衰老是我们这个时代最重要的挑战,也是最大的机遇。

From market entry to listings to cross-border capital formation, we help visionary companies scale between East and West. Age, but less.

从市场进入、挂牌上市到跨境资本融通,我们助力有远见的企业在东西方之间实现规模化扩张。增长年岁,而不衰老。

Longevity Science长寿科学 AI HealthcareAI医疗健康 Biotechnology生物技术 Drug Discovery新药研发 Silver Economy银发经济 CDMO PartneringCDMO合作 GBA Access大湾区通道

"The companies that solve aging will define the next century of medicine. We help them find their home in Asia."

「攻克衰老难题的企业,将定义下一个世纪的医学格局。我们助力这些企业在亚洲找到立足之地。」

🧬
Aging & Longevity
老龄化与长寿科技
310M+ Chinese seniors and rising. The world's largest, fastest-growing demand pool — and a national policy mandate to act.
中国60岁以上人口超3.1亿且持续增长——全球规模最大、增速最快的需求市场,亦是国家政策重点扶持方向。
AI × Biology
AI × 生物科学
Machine learning is compressing discovery cycles and lowering cost across drugs, diagnostics, and materials.
机器学习正在压缩新药研发周期,大幅降低药物、诊断及材料领域的成本。
🌏
Capital into Asia
资本涌入亚洲
Hong Kong connects global innovation to deep patient capital and Asia's largest consumer growth markets.
香港连接全球创新与亚洲深厚的耐心资本,以及亚洲最大的消费增长市场。

What We Do

我们的服务

Three services. One operating platform.

三大服务路径,一体化运营平台。

We are not a fund. We are your cross-border operating partner — building the commercial, regulatory, and manufacturing foundation companies need to scale in Asia.

我们不是基金。我们是您的跨境运营伙伴——为企业在亚洲的规模化扩张构建商业、合规及制造基础设施。

Service 01服务路径 01

Business Landing Acceleration

企业落地加速服务

We act as your in-market operator in Hong Kong and the Greater Bay Area — handling everything required to turn a foreign company into a functioning local entity with real commercial traction.

我们担任您在香港及大湾区的驻地运营伙伴——全权处理外资企业在当地设立实体、实现商业化落地所需的一切事务。

  • HK entity formation, BRN registration & company secretarial
  • Corporate structuring, organisation design & strategy planning
  • Accounting, tax planning & reporting systems
  • Grant identification & drafting (InnoHK, ITF, HKIDS, Cyberport)
  • Introductions to HKSTP ecosystem, GBA research institutes, hospital groups & CROs
  • Buyer, manufacturer & distributor matching across GBA
  • IP structuring, patent liaison & R&D co-development framing
  • Share/option plan design; investor process support; M&A facilitation
  • 香港实体注册、商业登记及公司秘书服务
  • 集团架构设计、组织规划及战略布局
  • 会计核算、税务筹划及财务报告体系搭建
  • 政府资助识别与申请(InnoHK、ITF、HKIDS、数码港)
  • 对接香港科技园生态圈、大湾区研究院、医院集团及CRO
  • 大湾区买家、制造商及分销商匹配对接
  • 知识产权架构、专利协调及研发合作框架
  • 股权/期权激励设计、投资者流程支持及并购协助
Entity Setup实体设立 Grant Writing资助申请 GBA Network大湾区资源 IP Structuring知识产权架构
Service 02服务路径 02

Local CDMO & Manufacturing Partnering

本地CDMO及制造合作

For biotech, pharma, and MedTech founders with validated IP, we identify and broker access to CDMOs and manufacturing partners across Hong Kong, GBA, and Southeast Asia — cutting time and cost from bench to production.

针对拥有经验证知识产权的生物科技、制药及医疗器械创始人,我们在香港、大湾区及东南亚识别并对接合适的CDMO及制造合作伙伴——大幅缩短从研发到生产的时间与成本。

  • CDMO identification and matchmaking across HK, Guangdong & ASEAN
  • Manufacturing and supply agreement negotiation
  • IP out-licensing to regional pharma, MedTech & manufacturing partners
  • Asset licensing deal structuring and milestone architecture
  • GMP readiness, quality systems & regulatory filing support
  • R&D co-development with local academic and institute partners
  • 香港、广东及东盟CDMO识别与精准匹配
  • 制造及供应协议谈判
  • 知识产权向区域制药、医疗器械及制造伙伴的授权转让
  • 资产授权交易架构及里程碑体系设计
  • GMP合规准备、质量体系及法规申报支持
  • 与本地学术机构及研究院联合研发合作
CDMO AccessCDMO对接 IP Out-Licensing知识产权授权 GMP ReadinessGMP合规
What to Expect
预期成果
Bench to Production
从实验室到生产线
CDMO networkCDMO网络HK and China's GBA, Southeast Asia香港、大湾区及东南亚
Partnership target合作目标LOI / MOU within 6 months6个月内签署意向书
Scope服务范围Flexible — discuss with us灵活定制,欢迎洽谈
Service 03服务路径 03

Venture Building & Operational Integration

创投孵化与运营整合

For companies that need more than advisory — we embed operationally, building end-to-end commercial infrastructure from upstream procurement and manufacturing through to downstream market delivery across Asia.

针对需要深度支持的企业——我们深度嵌入运营,构建从上游采购、制造到下游亚洲市场交付的全链路商业基础设施。

  • Embedded operational leadership — External COO model
  • End-to-end value chain oversight: procurement, manufacturing, distribution
  • Strategic alliances with industry, academic institutions & public sector
  • Product commercialisation across health-tech, medical device & supplement verticals
  • Co-build ventures alongside founding teams from pre-incorporation
  • Ecosystem introductions: HKSTP, Cyberport, InnoHK clusters
  • 嵌入式运营领导团队——外部COO模式
  • 全链路价值链管理:采购、制造、分销
  • 与产业界、学术机构及公共部门建立战略联盟
  • 健康科技、医疗器械及营养补充品领域产品商业化
  • 与创始团队联合孵化,从公司注册前阶段全程参与
  • 生态圈引荐:香港科技园、数码港、InnoHK创新集群
External COO外部COO Alliance Network战略联盟 Major longevity clusters全球长寿产业集群 Industry · Academic · Public产学研政
What to Expect
预期成果
Full Operating Partnership
全面运营合作伙伴关系
Alliance network联盟网络Industry · Academic · Public产学研政
Ecosystem access生态资源Major global longevity clusters全球主要长寿产业集群
Transparency透明度Full status visibility at every stage各阶段全程可视化
Scope服务范围Tailored to your stage and goals依据阶段与目标定制

Our Team

我们的团队

Built across capital markets, science, and Asia.

横跨资本市场、科学前沿与亚洲生态。

View full team profiles → 查看完整团队介绍 →

Justin Tso
Justin Tso
Justin Tso 曹展立
Co-Founder & General Partner
联合创始人兼普通合伙人
Donny Siu
Donny Siu
Donny Siu 萧觀明
Director, Acceleration Services
加速服务总监
Aaisha Bhuiyan
Aaisha Bhuiyan
General Partner
普通合伙人
Doug Nissinoff
Doug Nissinoff
Venture Partner
创投合伙人
Dr. Rima Patel
Dr. Rima Patel
Venture Partner
创投合伙人
Elena Liapounova
Elena Liapounova
Investor Relations
投资者关系
Sergei Petukhov
Sergei Petukhov
Venture Partner
创投合伙人

Market Intelligence

市场洞察

The longevity economy, region by region.

银发经济,逐区深度解析。

Click a region on the map to explore aging market data and AGVC's strategic focus.

点击地图上的区域,深入了解各地老龄化市场数据与AGVC的战略布局。

Loading map…地图加载中…

Longevity Pulse

长寿产业动态

What's happening in the longevity ecosystem.

长寿生态系统的最新动态。

Updated periodically · Click any card to read

定期更新 · 点击卡片阅读全文

🧬
Research科研
2025 · Nature Aging
2025 · 《自然衰老》
Targeting the Hallmarks of Aging: From Senolytics to Epigenetic Reprogramming
攻克衰老标志:从衰老细胞清除到表观遗传重编程
Nature Aging examines the frontier of longevity medicine — from senolytic compounds to partial epigenetic reprogramming — and what it means for the next decade of therapeutic development in Asia.
《自然衰老》深入探讨长寿医学的科研前沿——从衰老细胞清除剂到局部表观遗传重编程——以及这对未来十年亚洲治疗领域发展的深远影响。
🏛️
Policy政策
2025 · WHO
2025 · 世界卫生组织
Global Report on Ageing and Health: Asia's Silver Economy Demand Accelerates
全球老龄化与健康报告:亚洲银发经济需求加速释放
The WHO's latest update highlights that Asia accounts for over 55% of the world's elderly population — and demand for longevity medicine and care-tech is outpacing supply.
世卫组织最新报告指出,亚洲老龄人口占全球总量逾55%——长寿医学与护理科技的市场需求正快速超越供给能力。
🤖
Market市场
2025 · SCMP
2025 · 南华早报
Hong Kong as Asia's Longevity Hub: Capital, Biotech, and the GBA Opportunity
香港:亚洲长寿科技枢纽——资本、生物科技与大湾区机遇
Hong Kong's unique position — bridging global science with Chinese capital and the GBA's manufacturing depth — is making it the defining gateway for longevity companies scaling into Asia.
香港的独特优势——连接全球科研、中国资本与大湾区制造深度——正使其成为长寿科技企业进军亚洲的核心门户。
More at longevity.technology 更多资讯:健康管理》

Where We Operate

我们的布局

A connected ecosystem across East and West.

中国与亚太抗衰及银发经济脉搏。

AGVC ecosystem
Hong Kong
香港
Our home base. Deep biotech infrastructure, government grant ecosystems, and direct access to China's manufacturing and hospital networks through the Greater Bay Area.
我们的核心基地。拥有深厚的生物科技基础设施、政府资助生态体系,并通过大湾区直连中国制造及医院资源网络。
Greater China
大中华区
CDMO networks, CROs, research institutes, and one of the world's largest aging consumer markets — with government policy actively driving the silver economy.
CDMO网络、CRO机构、科研院所,以及全球规模最大的老龄消费市场之一——政府政策正积极推动银发经济发展。
North America
北美洲
Where the world's most advanced longevity science originates. We connect US and Canadian deep-tech founders to Asian capital, partners, and commercialisation pathways.
全球最前沿的长寿科学发源地。我们将美国和加拿大的深度科技创始人与亚洲资本、合作伙伴及商业化路径紧密相连。
Asia-Pacific & Beyond
亚太地区及更广泛市场
Japan, Singapore, Korea, and the Middle East — mature aging markets, sophisticated payers, and sovereign capital increasingly focused on the longevity economy.
日本、新加坡、韩国及中东地区——成熟的老龄化市场、专业的付费机构,以及日益聚焦长寿经济的主权资本。

Get In Touch

联系我们

Building the future of longevity? Let's talk.

正在构建长寿科技的未来?欢迎对话。

We work with scientists, founders, and partners navigating cross-border commercialisation in the longevity space.

我们与科学家、创始人及合作伙伴携手,共同探索长寿产业的跨境商业化路径。

We respond within 3–5 business days.

我们将在3至5个工作日内回复。

🧬
AGVC Advisor
AGVC 顾问
● Online
Hi! I can help you figure out which of our services fits your situation best. What describes you?
您好!我可以帮您了解哪项服务最适合您的情况。请问您的身份是?